aqXFqROlmGb |
| xZyqmGBUIADdqqAZFX [2019-05-31] |
| I've only just arrived http://9taxi.in.net www.9taxi.com Access to full, appropriately de-identified datasets from clinical trials can benefit the biopharmaceutical industry by improving the efficiency of drug development, enhancing comparative-effectiveness analyses and reducing duplication of effort among trial sponsors, officials from the European Medicines Agency (EMA) insist.
|
|